Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. - Wikidata - awgldk - TriplyDB

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q42008293

about

Identification of a novel gene family that includes the interferon-inducible human genes 6-16 and ISG12 Epstein Barr virus/complement C3d receptor is an interferon alpha receptor Era of direct acting antivirals in chronic hepatitis C: Who will benefit?Non-A, non-B hepatitis.Hepatitis C virus. A review.Chronic non-A, non-B hepatitis: role of hepatitis C virus.Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis.Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA Amantadine therapy for chronic hepatitis C Morphine Withdrawal Enhances Hepatitis C Virus Replicon Expression Morphine Enhances Hepatitis C Virus (HCV) Replicon Expression Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes IgG1 anti-P2 as a marker of response to interferon in patients with chronic hepatitis C A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans Comparison of a competitive combined reverse transcription-PCR assay with a branched-DNA assay for hepatitis C virus RNA quantitation A rational approach to the management of hepatitis C infection Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites Hepatology Expression of processed core protein of hepatitis C virus in mammalian cells Gastroenterology Parenterally acquired non-A non-B hepatitis ten years on: advances in diagnosis and therapy Automated quantitative determination of hepatitis C virus viremia by reverse transcription-PCR Soluble interferon-alpha receptor molecules are present in body fluids The biology of interferon-alpha and the clinical significance of anti-interferon antibodies.Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy Evaluated outcomes in patients with Chronic Hepatitis C.Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.Cell-based and animal models for hepatitis B and C viruses.Efficacy and tolerability of combination therapy with interferon-alfa plus ribavirin in patients with chronic hepatitis C virus infection: a single-center study in relapsers and nonresponders to previous treatment with high-dose interferon-alfa mono Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2.Sexually transmitted hepatitis: a review.Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepat Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.Interferon-alpha-induced acute renal allograft rejection.

P2860

Q21266614-80830F71-CF5D-4F9C-858A-7721F1019CE3 Q24561504-426C5098-9E47-456D-A383-07C8AD7D485E Q26777506-9E960D6D-63E0-414D-BAEE-FD493DDA6653 Q27469293-B519A18D-4380-44D1-8D34-A18F1F23E42D Q27469295-13FBF0F9-6D38-4E03-B34A-DF13ADFAC535 Q27469328-E603AC51-49F6-4787-924B-B1C0B8F691A7 Q27469549-3E9B7741-588B-49A2-A46C-5887505C0AA3 Q27472996-3E5D4ED3-5C47-4440-855B-D2560DD721B8 Q27473012-05E90A25-7799-414C-A3CD-6571958B7BC1 Q27473016-5E788D15-0B29-47C7-9B9B-FA4766C59944 Q27473307-CAD57A2E-920C-4C4E-8DBF-54E943C805B0 Q27477516-D83D8877-845D-492A-86E3-2F3D227E039A Q27478396-DAEEAB0F-52CB-44FC-9A2B-09793D040F6C Q27478466-8A97B02E-053A-4E88-94D5-87DFD6EADAFD Q27480411-76D1DD2D-3AD3-4319-A7C5-8319ABD23673 Q27480600-44133FC9-697B-4843-AA0C-0A4F109D0B11 Q27485126-4244E47E-FEF8-43FB-BCFC-E1B4E0B73752 Q27485763-71290353-F4E8-42B9-B3F9-364E793171B6 Q27485902-3C4EC487-3893-412E-8336-7FFDC5E61C9F Q27486010-F43ECDD7-FBA9-48AE-8333-B216C42B8A95 Q27486027-182FB28E-3A7A-47C4-9860-56BCB626B6C5 Q27486176-49AF4FA4-78B1-4355-B4D0-660C2AA69C5E Q27486227-4D28D5D6-3EC1-4A3E-B63D-892FED448275 Q27486369-32059DDE-F433-4B59-8B00-5B7608EF4280 Q27486372-0FE46876-30A9-4173-9A52-93A983A42A85 Q27487880-082919A3-D4AE-4161-9918-345D63613467 Q28609446-C9552076-94B7-4AF6-A460-2BF42B18F781 Q30431132-CD96B534-2377-4DC2-9651-287CFF9ACA95 Q33592250-EAA162F9-B214-4FB6-8E7B-95EEEE0419A5 Q33596752-DB09F7F8-CB84-4838-8E98-0F4E4FF968C6 Q33622970-B28AE78F-34DB-40DB-88D1-037462D66468 Q33702348-A0384EA5-BCDC-4C56-BDC0-40C56B3B88DA Q33739046-97356430-152C-4E45-AEB8-F3EC0FC61136 Q33788596-CD6D5B61-6394-47B9-A2E9-5F5293C91A36 Q33933564-197D5F17-3B44-4E97-9636-14EEC3659EE7 Q34026121-334E089D-7C25-4764-B28F-3955C9F70E7C Q34164822-C90500BE-32FB-432F-AA06-B6AD69F89921 Q34215894-E5E7DAEA-1880-4953-88F9-EE39D9512B67 Q34225751-48450CFF-7053-4405-B5B7-1FF9198AEF64 Q34232396-320EFCC0-7D1B-4AA8-8BE2-A1A95ADE37DF

P2860

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q42008293

description

1989 nî lūn-bûn

@nan

1989年の論文

@ja

1989年学术文章

@wuu

1989年学术文章

@zh-cn

1989年学术文章

@zh-hans

1989年学术文章

@zh-my

1989年学术文章

@zh-sg

1989年學術文章

@yue

1989年學術文章

@zh

1989年學術文章

@zh-hant

name

Recombinant interferon alfa th ...... ind, placebo-controlled trial.

@en

Recombinant interferon alfa th ...... ind, placebo-controlled trial.

@nl

type

label

Recombinant interferon alfa th ...... ind, placebo-controlled trial.

@en

Recombinant interferon alfa th ...... ind, placebo-controlled trial.

@nl

prefLabel

Recombinant interferon alfa th ...... ind, placebo-controlled trial.

@en

Recombinant interferon alfa th ...... ind, placebo-controlled trial.

@nl

P1433

Q42008293-1FDCDB34-D252-43C3-8F4B-D37C4C2FA6BD

P1476

Q42008293-75FF81BE-3F1E-4869-8BDF-BAB6EBA19FAF

P2093

Q42008293-01CFC116-82FE-4AAF-B07F-7C8308A83445

Q42008293-18F503F9-0931-48D8-A154-A9444F4F6C11

Q42008293-3599C8F6-A232-4FC1-8C02-A31A749E5F45

Q42008293-36FBE214-035B-48CB-B8FC-B45FF5004C9F

Q42008293-4A371BDA-CBBC-4E70-9B29-2B6953704D4A

Q42008293-5873B403-8B6B-4079-B718-0CDAB93BE36A

Q42008293-75204F0B-4AAD-467E-A801-53B301FA4151

Q42008293-9514990D-0550-492D-8E55-B73E7147CB29

Q42008293-C7D07778-AF31-443D-BBF0-BC5F62E2CD1A

P304

Q42008293-1A55050A-8DF6-4F4E-BFAA-E4E5D14664A3

P31

Q42008293-BA11F1FD-4581-4CD6-8651-E57C5C139CA4

P356

Q42008293-085BBCDD-9846-4834-A8E4-705E1A537552

P407

Q42008293-A1B0BCFE-BC6A-454E-8D6C-2FD8F5627EE3

P433

Q42008293-C1287570-C79B-4054-A261-9E3C2DE3C755

P478

Q42008293-9D23EAE8-FC4D-46B4-A41C-06C4EE1C2AAA

P577

Q42008293-9FC97F70-21B6-4F52-8AAC-9940453A6046

P698

Q42008293-815F4C17-5386-4FCB-A80F-B5463C853AB0

P921

Q42008293-AF93E56E-4D06-4D60-9C7C-5B6D4E0D9D05

P356

NEJM198911303212204

P1433

The New England Journal of Medicine

P1476

Recombinant interferon alfa th ...... ind, placebo-controlled trial.

@en

P2093

Banks SM

http://www.w3.org/2001/XMLSchema#string

Di Bisceglie AM

http://www.w3.org/2001/XMLSchema#string

Goodman Z

http://www.w3.org/2001/XMLSchema#string

Hoofnagle JH

http://www.w3.org/2001/XMLSchema#string

Kassianides C

http://www.w3.org/2001/XMLSchema#string

Lisker-Melman M

http://www.w3.org/2001/XMLSchema#string

Martin P

http://www.w3.org/2001/XMLSchema#string

Murray L

http://www.w3.org/2001/XMLSchema#string

Waggoner J

http://www.w3.org/2001/XMLSchema#string

P304

1506-1510

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJM198911303212204

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

321

http://www.w3.org/2001/XMLSchema#string

P577

1989-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

2509917

http://www.w3.org/2001/XMLSchema#string

P921